Mark Andrew Wilson insider trades: Nektar Therapeutics (NKTR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
25 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | NKTR | ↓ Sell | 630 | $54.28 | $34K | Direct | Nov 25, 2025 (0d) |
| Aug 19, 2025 | NKTR | ↓ Sell | 676 | $26.59 | $18K | Direct | Aug 21, 2025 (2d) |
| May 19, 2025 | NKTR | ↓ Sell | 9,996 | $0.67 | $7K | Direct | May 21, 2025 (2d) |
| Feb 19, 2025 | NKTR | ↓ Sell | 11,040 | $1.01 | $11K | Direct | Feb 21, 2025 (2d) |
| Dec 24, 2024 | NKTR | ↓ Sell | 49,962 | $0.90 | $45K | Direct | Dec 26, 2024 (2d) |
| Nov 19, 2024 | NKTR | ↓ Sell | 6,407 | $1.01 | $6K | Direct | Nov 20, 2024 (1d) |
| Aug 19, 2024 | NKTR | ↓ Sell | 5,651 | $1.28 | $7K | Direct | Aug 20, 2024 (1d) |
| May 17, 2024 | NKTR | ↓ Sell | 6,260 | $1.75 | $11K | Direct | May 20, 2024 (3d) |
| Feb 20, 2024 | NKTR | ↓ Sell | 7,606 | $0.68 | $5K | Direct | Feb 22, 2024 (2d) |
| Nov 17, 2023 | NKTR | ↓ Sell | 7,179 | $0.49 | $4K | Direct | Nov 20, 2023 (3d) |
| Aug 16, 2023 | NKTR | ↓ Sell | 7,221 | $0.78 | $6K | Direct | Aug 17, 2023 (1d) |
| May 16, 2023 | NKTR | ↓ Sell | 7,543 | $0.72 | $5K | Direct | May 17, 2023 (1d) |
| Feb 16, 2023 | NKTR | ↓ Sell | 8,275 | $3.00 | $25K | Direct | Feb 17, 2023 (1d) |
| Nov 16, 2022 | NKTR | ↓ Sell | 8,690 | $3.57 | $31K | Direct | Nov 18, 2022 (2d) |
| Aug 16, 2022 | NKTR | ↓ Sell | 3,189 | $4.76 | $15K | Direct | Aug 17, 2022 (1d) |
| May 16, 2022 | NKTR | ↓ Sell | 3,136 | $3.95 | $12K | Direct | May 17, 2022 (1d) |
| Feb 16, 2022 | NKTR | ↓ Sell | 3,661 | $10.95 | $40K | Direct | Feb 18, 2022 (2d) |
| Nov 16, 2021 | NKTR | ↓ Sell | 6,564 | $13.16 | $86K | Direct | Nov 17, 2021 (1d) |
| Aug 16, 2021 | NKTR | ↓ Sell | 1,910 | $13.83 | $26K | Direct | Aug 18, 2021 (2d) |
| May 17, 2021 | NKTR | ↓ Sell | 1,917 | $18.30 | $35K | Direct | May 19, 2021 (2d) |
| Feb 16, 2021 | NKTR | ↓ Sell | 2,173 | $22.37 | $49K | Direct | Feb 18, 2021 (2d) |
| Feb 3, 2021 | NKTR | ↓ Sell | 5,344 | $19.45 | $104K | Direct | Feb 4, 2021 (1d) |
| Nov 16, 2020 | NKTR | ↓ Sell | 1,539 | $16.93 | $26K | Direct | Nov 18, 2020 (2d) |
| Aug 17, 2020 | NKTR | ↓ Sell | 1,529 | $19.67 | $30K | Direct | Aug 19, 2020 (2d) |
| May 18, 2020 | NKTR | ↓ Sell | 1,529 | $22.51 | $34K | Direct | May 20, 2020 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NKTR insiders
Open-market trades in the last 12 months
About Mark Andrew Wilson's insider trades
Mark Andrew Wilson is Chief Legal Officer at Nektar Therapeutics (NKTR). Since May 18, 2020, Mark has reported no open-market purchases and 25 sales worth $674K on SEC Form 4. In the last 12 months: 1 sale ($34K).
Their filings also include grants and awards (10 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NKTR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.